Lisa Rojkjaer
Chief Tech/Sci/R&D Officer at RIGEL PHARMACEUTICALS, INC.
Net worth: 49 049 $ as of 2024-03-30
Profile
Lisa Rojkjaer is currently the Chief Medical Officer & Executive Vice President at Rigel Pharmaceuticals, Inc. She previously held positions as the Head-AML Global Clinical Program at Novartis Oncology, Inc. from 2013 to 2016, Chief Medical Officer at Sunesis Pharmaceuticals, Inc., Vice President & Head-Clinical Development at MorphoSys AG, Head-Clinical Development & Hematology at Novo Nordisk, Inc., Chief Medical Officer at Molecular Partners AG, and Head-Global Clinical Program at Novartis Pharma AG.
From 2016 to 2020, she served as the Chief Medical Officer at Nordic Nanovector ASA, and from 2020 to 2023, she held the same position at Viracta Therapeutics, Inc. Dr. Rojkjaer also worked as the Chief Medical Officer at Sangamo Therapeutics, Inc. and Viracta Subsidiary, Inc. She obtained her doctorate degree from the University of Toronto.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2023-04-18 | 48,087 ( 0.12% ) | 49 049 $ | 2024-03-30 |
Lisa Rojkjaer active positions
| Companies | Position | Start |
|---|---|---|
| RIGEL PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 2024-03-11 |
Former positions of Lisa Rojkjaer
| Companies | Position | End |
|---|---|---|
| VIRACTA THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 2023-05-04 |
| THOR MEDICAL | Chief Tech/Sci/R&D Officer | 2020-03-31 |
Novartis Oncology, Inc.
 Novartis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Novartis Oncology, Inc. provides healthcare solutions. The firm offers medicines, eye care and generic pharmaceuticals. It also offers patient declaration, patient support and assistance, and additional resources. The company is headquartered in East Hanover, NJ. | Corporate Officer/Principal | 2016-10-31 |
| SANGAMO THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | - |
Viracta Subsidiary, Inc.
 Viracta Subsidiary, Inc. BiotechnologyHealth Technology Viracta Subsidiary, Inc. engages in the development of proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr virus. Its platform is designed as a targeted approach to treat a range of viral-associated cancers and other serious diseases. The company was founded by Ronald J. Berenson, Douglas V. Faller, George C. Hillman, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos, and Robert Williams and is headquartered in Cardiff, CA. | Chief Tech/Sci/R&D Officer | - |
Training of Lisa Rojkjaer
| University of Toronto | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 5 |
|---|---|
| RIGEL PHARMACEUTICALS, INC. | Health Technology |
| SANGAMO THERAPEUTICS, INC. | Health Technology |
| MORPHOSYS AG | Health Technology |
| MOLECULAR PARTNERS AG | Health Technology |
| VIRACTA THERAPEUTICS, INC. | Health Technology |
| Private companies | 6 |
|---|---|
Novartis Oncology, Inc.
Novartis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Novartis Oncology, Inc. provides healthcare solutions. The firm offers medicines, eye care and generic pharmaceuticals. It also offers patient declaration, patient support and assistance, and additional resources. The company is headquartered in East Hanover, NJ. | Health Technology |
Sunesis Pharmaceuticals, Inc.
 Sunesis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sunesis Pharmaceuticals, Inc. engages in the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. The firm's activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The company was founded on February 10, 1998 and is headquartered in South San Francisco, CA. | Health Technology |
Novo Nordisk, Inc.
 Novo Nordisk, Inc. BiotechnologyHealth Technology Novo Nordisk, Inc. operates diabetes care company. It offers biopharmaceuticals, chronic weight management, human growth hormone therapy and hemophilla management services. The firm also provides rare bleeding disorders, growth hormone related disorders, and women's health. The company was founded in 1982 and is headquartered in Plainsboro, NJ. | Health Technology |
Novartis Pharma AG
 Novartis Pharma AG Pharmaceuticals: MajorHealth Technology Novartis Pharma AG engages in the research in as well as the production and distribution of pharmaceutical, chemical, medical, and biotechnological products. It also provides related services. The company was founded on October 25, 1989 and is headquartered in Basel, Switzerland. | Health Technology |
Nordic Nanovector ASA
 Nordic Nanovector ASA Pharmaceuticals: MajorHealth Technology Nordic Nanovector ASA is a biopharmaceutical company, which engages in the development, marketing, and sale of medical products and equipment for anticancer therapeutics for haematological cancers. The firm offers the Betalutin which is an antibody radionuclide conjugates for the treatment of non-Hodgkin lymphoma. It operates through the following geographical segments: Norway, Switzerland, and the United Kingdom. The company was founded by Roy Hartvig Larsen, Oyvind Sverre Bruland, and Jostein Dahle on July 2, 2009 and is headquartered in Oslo, Norway. | Health Technology |
Viracta Subsidiary, Inc.
Viracta Subsidiary, Inc. BiotechnologyHealth Technology Viracta Subsidiary, Inc. engages in the development of proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr virus. Its platform is designed as a targeted approach to treat a range of viral-associated cancers and other serious diseases. The company was founded by Ronald J. Berenson, Douglas V. Faller, George C. Hillman, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos, and Robert Williams and is headquartered in Cardiff, CA. | Health Technology |
- Stock Market
- Insiders
- Lisa Rojkjaer
